Objective. To assess the overall safety, including rare events, of intravenous (IV) abatacept
treatment in rheumatoid arthritis (RA). Methods. Data from 8 clinical trials of IV abatacept in …

Objective To investigate the safety of long‐term subcutaneous (SC) abatacept treatment
using integrated clinical trial data obtained in patients with rheumatoid arthritis refractory to …

… Rodriguez, Delaet, and Elegbe own stock or stock options in Bristol-Myers Squibb. Dr.
Corbo owns stock or stock options in BristolMyers Squibb and has received fees from Bristol-…

Objectives To assess the effect of a temporary interruption in subcutaneous (SC) abatacept
on immunogenicity, safety and efficacy in patients with active rheumatoid arthritis despite …

Objective To assess safety, immunogenicity and efficacy in rheumatoid arthritis (RA) patients
switched from long-term intravenous to subcutaneous (SC) abatacept. Methods In this …

Objective. Assess longterm tolerability, safety, and efficacy of subcutaneous (SC) abatacept (ABA)
in methotrexate-refractory patients with rheumatoid arthritis (RA). Methods. The phase …

The ethical basis for the US Food and Drug Administration(FDA) required initial pediatric
study plan (iPSP) 18 and the European Medicines Agency (EMA) equivalent pediatric …

Three of thirty-six monoclonal antibodies were found to cause irreversible inactivation of
type 1 poliovirus at 39 degrees C but not at 37 degrees C. Neutralization at 37 degrees C …

Binding of bivalent antibody can neutralize picornaviruses by a variety of mechanisms. Some
monoclonal antibodies can irreversibly neutralize the virus at temperatures that are higher …

Three out of 36 poliovirus type 1-specific monoclonal antibodies which, at 37 C in a medium
of normal ionic strength (μ = 0·16), caused only aggregative neutralization (reversible by …